好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Multimodal Characterization of Delayed Diagnosis in ALS
Aging, Dementia, and Behavioral Neurology
S13 - Behavioral and Cognitive Neurology: Behavioral Neurology, Aging, and Dementia (2:28 PM-2:39 PM)
009
There is significant heterogeneity in the phenotypic expression of ALS including site of onset, relative degree of upper (UMN) and lower motor neuron (LMN) dysfunction, and presence of genetic mutations. As a result, it can take over a third of the overall disease duration to accurately diagnose ALS and initiate clinical care or trials enrollment.  We performed a multimodal characterization of ALS patients with long diagnostic delay to identify features facilitating an earlier diagnosis.

To investigate the clinical, genetic, cerebrospinal fluid (CSF) and MRI features of ALS patients with a long diagnostic delay in an effort to facilitate earlier diagnosis.

A retrospective assessment of 934 patients who eventually met criteria for probable or definite ALS. Linear regression models were applied to test the role of clinical and genetic features in predicting diagnostic delay (time from symptoms onset to diagnosis). Patients were subsequently divided into “short” (N=551) and “long” (N=383) diagnostic delay groups (defined with a median split of 12 months) and clinical, CSF (including total tau (tTau) and neurofilament light chain (NfL)) and cortical thickness MRI measurements were acquired and compared between the two groups.
Significant predictors for a longer diagnostic delay included: spinal onset, selective UMN dysfunction, an initial suspected El Escorial diagnosis and the absence of a genetic mutation. Patients with a long diagnostic delay relative to cases with short diagnostic delay had a slower clinical progression rate and a longer survival. CSF tTau, CSF NfL, and cortical thinning in primary motor and fronto-temporal regions were significantly reduced in the longer relative to shorter diagnostic delay group.
While altered biomarkers can identify shorter diagnostic delay patients, cases with longer delay may exhibit spinal onset, UMN dysfunction, and sporadic disease.  Clinicians should consider these factors in an effort to accelerate a confirmed ALS diagnosis.
Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
Katerina Placek No disclosure on file
Murray Grossman, MD, FAAN (University of Pennsylvania) Dr. Grossman has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Grossman has received research support from NIH.
Colin Quinn, MD (University of Pennsylvania) Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx Pharmaceuticals. Dr. Quinn has received personal compensation in the range of $0-$499 for serving as a Consultant for Amicus. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta Therapeutics. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Quinn has received personal compensation in the range of $0-$499 for serving as a Consultant for Clene Nanomedicine. Dr. Quinn has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Partners Health Care. Dr. Quinn has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Robins Kaplan.
Leo McCluskey, MD (Atrium Health Neurosciences Institute) No disclosure on file
Lauren B. Elman, MD Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. Dr. Elman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Edgewise Therapeutics. Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis Pharamaceuticals. Dr. Elman has received publishing royalties from a publication relating to health care.
Corey McMillan, PhD (University of Pennsylvania) Dr. McMillan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. McMillan has received research support from Biogen. The institution of Dr. McMillan has received research support from NIH.